Imaging company Dilon Diagnostics has landed a partnership to distribute a molecular breast imaging system from GE Healthcare in select, undisclosed global geographies. The offering is intended to complement Dilon's own molecular imaging offerings.
The effective diagnosis and treatment of cancer has remained a largely First World problem so far. But someday, perhaps sooner rather than later, that's expected to no longer be the case. A coalition has created a global initiative to improve access to some of the most underserved populations in sub-Saharan Africa and Haiti.
GE Healthcare will work with Oregon Health & Science University to develop collaborative research programs in cardiovascular medicine, imaging and big data research. They expect to address essential questions about biology and medicine through the combination of the clinical expertise of OHSU and the technological facility of GE Healthcare.
The race is on to develop U.S. sources for a material necessary to create the most widely used radioisotope in medical diagnostic imaging. Now GE Healthcare and startup Shine Technologies have disclosed that they have successfully used GE's existing tech to create the common medical radioisotope technetium-99m (Tc‑99m) from molybdenum-99 (Mo-99) produced by Shine.
Call it a biopharma plant in a box--62 boxes actually. That is how many containers were shipped from a GE production facility to China to build GE's first prefab biologics plant for JHL Biotech, a company founded by U.S. biotech veterans working on biosimilars.
Oncology genomics player NeoGenomics is slated to buy GE cancer diagnostic unit Clarient Diagnostic Services in a cash and stock deal worth about $300 million. That's an impressive feat given that NeoGenomics' market cap was less than $350 million prior to the deal announcement.
GE Healthcare has staked a major claim in a field that's not well tended--the development of affordable medical technologies to improve health outcomes in the emerging markets. It's creating a devoted business called Sustainable Healthcare Solutions out of a combination of its operations in India, South Asia, Africa and Southeast Asia dedicated to serving 70 markets--and investing $300 million to back the effort.
Almost one year into the job, GE Healthcare President and CEO John Flannery recently outlined his strategy for returning the healthcare business to growth. It's an $18 billion business that accounts for about 16% of the conglomerate's total revenues. He affirmed that the business will remain within GE, despite ongoing restructuring involving the divestiture of the finance arm.
Earlier this year, GE Healthcare CEO Jeff Immelt cited hospitals as a potentially lucrative source of growth for the company, pointing to a shift toward major contracts amid healthcare reform. Now, the company is taking a big step in that direction, inking a deal with Philadelphia's Temple University Health System to improve the medical center's radiology technology while helping it cut costs.
GE Healthcare got an FDA green light for its low-dose computer tomography (CT) lung cancer screening device, a feather in the company's cap as it deepens its dive into diagnostics imaging.